한글목차

미만성 거대 B세포 림프종 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 51억 달러에서 2026년에는 54억 8,000만 달러로, CAGR 7.6%로 확대될 것으로 예상됩니다. 지난 수년간의 성장에는 비호지킨림프종 발생률 증가, 리툭시맙 기반 요법의 광범위한 채택, 진단 정확도 향상, 병원 기반 종양학 인프라 확충, 림프종 치료 옵션에 대한 인식 개선 등이 주요 요인으로 작용한 것으로 보입니다.

미만성 거대 B세포 림프종 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 75억 4,000만 달러에 달하고, CAGR은 8.3%가 될 전망입니다. 예측 기간 동안 성장 요인으로는 표적 치료제 파이프라인 확대, 면역항암제 병용요법 증가, 종양 전문 클리닉 확대, 신흥국의 의료비 지출 증가, 맞춤형 의료 접근법의 발전 등을 꼽을 수 있습니다. 주요 동향으로는 면역요법 기반 치료 요법의 확대, 병용 화학요법 프로토콜의 채택 증가, 단클론항체 요법의 사용 확대, 맞춤형 치료 경로의 성장, 치료 내성 개선에 대한 집중 강화 등이 예측됩니다.

확산성 대세포 B세포 림프종(DLBCL)의 발생률 증가는 향후 몇 년 동안 확산성 대세포 B세포 림프종 치료제 시장의 성장을 견인할 것으로 예상됩니다. 미만성 거대 B세포 림프종은 림프계 내 B세포에서 발생하는 침습성 악성 종양으로, 빠르고 광범위한 종양 증식이 특징입니다. 비호지킨림프종(NHL)의 아형으로 분류됩니다. 미만성 거대 B세포 림프종 치료제는 악성 암세포를 효과적으로 표적화하고 조절하여 진단을 받은 환자의 임상적 결과를 개선하도록 설계되었습니다. 예를 들어, 미국의 비영리 건강단체인 미국암협회(American Cancer Society)의 추산에 따르면, 2023년에는 약 8만 550명(남성 4만 4,880명, 여성 3만 5,670명)이 비호지킨림프종 진단을 받고, 약 2만 180명이 이 질환으로 사망할 것으로 예상하고 있습니다. 사망할 것으로 예상됩니다. 따라서 미만성 거대 B세포 림프종 발생률의 증가는 해당 치료제 시장의 성장에 기여하고 있습니다.

미만성 거대 B세포 림프종 치료제 시장에서 사업을 전개하고 있는 주요 기업들은 치료 효과 향상과 재발 및 난치성 질환 환자들의 치료 옵션 확대를 목표로 신규 CD19 표적 면역치료제를 포함한 신약 개발에 집중하고 있습니다. 신규 CD19 표적 면역치료제는 B세포 림프종 세포에서 CD19 항원을 인식하여 항체 의존성 세포손상(ADCC) 및 면역세포 활성화 촉진과 같은 면역기전을 활성화시켜 보다 효과적인 종양세포 파괴를 유도하는 진보된 항체 기반 또는 항체 유래 치료법입니다. 예를 들어, 2023년 6월에는 Specialized Therapeutics Asia Pte Ltd가 개발한 MINJUVI(타파시티맙)가 호주 치료제품관리국(TGA)으로부터 승인을 받았습니다. MINJUVI는 레날리도마이드와의 병용요법으로 자가 줄기세포 이식이 불가능한 재발성 또는 불응성 미만성 거대 B세포 림프종 성인 환자를 대상으로 합니다. CD19를 표적으로 하는 면역치료제로서 B세포 림프종 세포의 면역매개성 제거를 촉진하며, 재발 환자에서 우수한 안전성과 높은 반응률을 보이고 있습니다. 이번 잠정적 규제 경로를 통한 승인과 'Modified Project Orbis' 이니셔티브에의 편입은 임상 2상L-MIND 시험의 유망한 결과를 바탕으로 환자 접근성을 가속화하기 위한 노력을 강조한 것입니다. 지속적인 승인은 확인 시험인 임상 3상 frontMIND 시험 결과에 따라 달라질 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Diffuse large B-cell lymphoma therapeutics encompass the treatment strategies and medications used to treat and manage diffuse large B-cell lymphoma, a form of non-Hodgkin lymphoma marked by the rapid growth of malignant B cells.

The primary drug classes involved in diffuse large B-cell lymphoma therapeutics include cisplatin, carboplatin, 5-fluorouracil (5-FU), docetaxel (Taxotere), paclitaxel (Taxol), methotrexate, and others. Cisplatin is a chemotherapy drug used to treat various cancers by interfering with the DNA structure of cancer cells, thereby preventing their division and growth. It is commonly used in combination chemotherapy regimens for certain lymphoma types as part of a multidrug treatment strategy. Treatment approaches include targeted therapy, immunotherapy, chemotherapy, and others, which are administered through oral, parenteral, and additional routes, and are utilized in hospitals, clinics, and other healthcare settings.

Tariffs have created both cost pressures and strategic shifts in the diffuse large B-cell lymphoma therapeutics market by increasing prices of imported active pharmaceutical ingredients, biologics, and injectable oncology drugs. These impacts are most pronounced across chemotherapy and immunotherapy segments, particularly in regions reliant on cross-border pharmaceutical supply chains such as asia-pacific and europe. Higher tariffs have led to increased treatment costs and procurement challenges for hospitals and clinics. However, tariffs have also encouraged local manufacturing, regional sourcing of APIs, and investments in domestic biopharmaceutical production, supporting long-term supply resilience.

The diffuse large b-cell lymphoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides diffuse large b-cell lymphoma therapeutics market statistics, including diffuse large b-cell lymphoma therapeutics industry global market size, regional shares, competitors with a diffuse large b-cell lymphoma therapeutics market share, detailed diffuse large b-cell lymphoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the diffuse large b-cell lymphoma therapeutics industry. This diffuse large b-cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diffuse large b-cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $5.1 billion in 2025 to $5.48 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising incidence of non-hodgkin lymphoma, widespread adoption of rituximab-based therapies, improved diagnostic accuracy, increasing hospital-based oncology infrastructure, growing awareness of lymphoma treatment options.

The diffuse large b-cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to pipeline growth of targeted therapies, increasing use of combination immunochemotherapy, expansion of oncology specialty clinics, rising healthcare expenditure in emerging economies, advancement in personalized medicine approaches. Major trends in the forecast period include expansion of immunotherapy-based regimens, rising adoption of combination chemotherapy protocols, increased use of monoclonal antibody therapies, growth in personalized treatment pathways, greater focus on improving treatment tolerability.

The rising incidence of diffuse large B-cell lymphoma (DLBCL) is anticipated to drive the expansion of the diffuse large B-cell lymphoma therapeutics market in the coming years. Diffuse large B-cell lymphoma is an aggressive malignancy that develops from B-cells within the lymphatic system and is marked by rapid and widespread tumor growth. It is classified as a subtype of non-Hodgkin lymphoma (NHL). Therapeutics for diffuse large B-cell lymphoma are designed to improve clinical outcomes for diagnosed patients by effectively targeting and controlling malignant cancer cells. For example, the American Cancer Society, a US-based voluntary health organization, estimated that in 2023 approximately 80,550 individuals, including 44,880 males and 35,670 females, would be diagnosed with non-Hodgkin lymphoma, with around 20,180 deaths attributed to the disease. Therefore, the growing incidence of diffuse large B-cell lymphoma is contributing to the growth of the diffuse large B-cell lymphoma therapeutics market.

Leading companies operating in the diffuse large B-cell lymphoma therapeutics market are focusing on the development of new drugs, including novel CD19-targeting immunotherapies, to improve treatment effectiveness and broaden options for patients with relapsed or refractory disease. Novel CD19-targeting immunotherapies are advanced antibody-based or antibody-derived treatments that identify the CD19 antigen on B-cell lymphoma cells and trigger immune mechanisms such as antibody-dependent cellular cytotoxicity or enhanced immune cell activation to promote more effective tumor cell destruction. For instance, in June 2023, MINJUVI (tafasitamab), developed by Specialized Therapeutics Asia Pte Ltd, received approval from the Therapeutic Goods Administration (TGA). MINJUVI, used in combination with lenalidomide, is indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant. As a CD19-targeting immunotherapy, the treatment enhances immune-mediated elimination of B-cell lymphoma cells and has demonstrated favorable safety and strong response rates in relapsed patients. Its approval through a provisional regulatory pathway and inclusion in the Modified Project Orbis initiative underscore efforts to accelerate patient access, based on encouraging results from the Phase 2 L-MIND study, with continued approval dependent on outcomes from the confirmatory Phase 3 frontMIND study.

In March 2023, invoX Pharma, a UK-based provider of innovative oncology and respiratory therapies, acquired F-star Therapeutics for approximately $161 million. Through this acquisition, invoX Pharma strengthened its global immuno-oncology pipeline by incorporating F-star's differentiated bispecific antibody platform, enhancing its capability to develop next-generation cancer immunotherapies. F-star Therapeutics is a US-based clinical-stage biopharmaceutical company specializing in the development of tetravalent bispecific antibodies for immunotherapy applications.

Major companies operating in the diffuse large b-cell lymphoma therapeutics market are Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG

North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large b-cell lymphoma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the diffuse large b-cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diffuse large B-cell lymphoma therapeutics market consists of revenues earned by entities by providing R-CHOP (rituximab (Rituxan), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The diffuse large B-cell lymphoma therapeutics market also includes sales of diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diffuse Large B-cell Lymphoma Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses diffuse large b-cell lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diffuse large b-cell lymphoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diffuse large b-cell lymphoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Cisplatin; Carboplatin; 5-fluorouracil; Docetaxel; Paclitaxel; Methotrexate; Other Drugs
• 2) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy; Other Therapies
• 3) By Route of Administration: Oral; Parenteral; Other Routes
• 4) By End User: Hospitals; Clinics; Other End-Users
• Companies Mentioned: Novartis AG; Pfizer Inc.; Merck & Co Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche AG; CTI BioPharma Corp.; Celltrion Healthcare Co Ltd.; Bristol-Myers Squibb Company; AbbVie Inc.; Gilead Sciences Inc.; Seagen Inc.; Kite Pharma Inc.; ADC Therapeutics SA; Bayer AG; Xencor Inc.; Autolus Therapeutics plc; Allogene Therapeutics Inc.; Spectrum Pharmaceuticals Inc.; AstraZeneca PLC; Aptevo Therapeutics Inc.; Takeda Pharmaceutical Company Limited; Johnson & Johnson; Celgene Corporation; Eli Lilly and Company; Sanofi SA; Seattle Genetics Inc.; Karyopharm Therapeutics Inc.; TG Therapeutics Inc.; MorphoSys AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Diffuse Large B-cell Lymphoma Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Diffuse Large B-cell Lymphoma Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Diffuse Large B-cell Lymphoma Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Diffuse Large B-cell Lymphoma Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Expansion Of Immunotherapy-Based Regimens
  • 4.2.2 Rising Adoption Of Combination Chemotherapy Protocols
  • 4.2.3 Increased Use Of Monoclonal Antibody Therapies
  • 4.2.4 Growth In Personalized Treatment Pathways
  • 4.2.5 Greater Focus On Improving Treatment Tolerability

5. Diffuse Large B-cell Lymphoma Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Specialty Cancer Centers
• 5.4 Research Institutes
• 5.5 Academic Medical Centers

6. Diffuse Large B-cell Lymphoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Diffuse Large B-cell Lymphoma Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Diffuse Large B-cell Lymphoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Diffuse Large B-cell Lymphoma Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Diffuse Large B-cell Lymphoma Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Diffuse Large B-cell Lymphoma Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Diffuse Large B-cell Lymphoma Therapeutics Market Segmentation

• 9.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
• 9.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
• 9.3. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Routes
• 9.4. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Other End-Users

10. Diffuse Large B-cell Lymphoma Therapeutics Market Regional And Country Analysis

• 10.1. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Diffuse Large B-cell Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market

• 11.1. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Diffuse Large B-cell Lymphoma Therapeutics Market

• 12.1. China Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Diffuse Large B-cell Lymphoma Therapeutics Market

• 13.1. India Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Diffuse Large B-cell Lymphoma Therapeutics Market

• 14.1. Japan Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Diffuse Large B-cell Lymphoma Therapeutics Market

• 15.1. Australia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market

• 16.1. Indonesia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market

• 17.1. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Diffuse Large B-cell Lymphoma Therapeutics Market

• 18.1. Taiwan Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Diffuse Large B-cell Lymphoma Therapeutics Market

• 19.1. South East Asia Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market

• 20.1. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Diffuse Large B-cell Lymphoma Therapeutics Market

• 21.1. UK Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Diffuse Large B-cell Lymphoma Therapeutics Market

• 22.1. Germany Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Diffuse Large B-cell Lymphoma Therapeutics Market

• 23.1. France Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Diffuse Large B-cell Lymphoma Therapeutics Market

• 24.1. Italy Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Diffuse Large B-cell Lymphoma Therapeutics Market

• 25.1. Spain Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market

• 26.1. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Diffuse Large B-cell Lymphoma Therapeutics Market

• 27.1. Russia Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Diffuse Large B-cell Lymphoma Therapeutics Market

• 28.1. North America Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Diffuse Large B-cell Lymphoma Therapeutics Market

• 29.1. USA Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Diffuse Large B-cell Lymphoma Therapeutics Market

• 30.1. Canada Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Diffuse Large B-cell Lymphoma Therapeutics Market

• 31.1. South America Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market

• 32.1. Brazil Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market

• 33.1. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Diffuse Large B-cell Lymphoma Therapeutics Market

• 34.1. Africa Diffuse Large B-cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Diffuse Large B-cell Lymphoma Therapeutics Market, Segmentation By Drug Class, Segmentation By Therapy, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Diffuse Large B-cell Lymphoma Therapeutics Market Regulatory and Investment Landscape

36. Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Diffuse Large B-cell Lymphoma Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Diffuse Large B-cell Lymphoma Therapeutics Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

37. Diffuse Large B-cell Lymphoma Therapeutics Market Other Major And Innovative Companies

• CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc.

38. Global Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Diffuse Large B-cell Lymphoma Therapeutics Market

40. Diffuse Large B-cell Lymphoma Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Diffuse Large B-cell Lymphoma Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Diffuse Large B-cell Lymphoma Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Diffuse Large B-cell Lymphoma Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer